Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a large decline in short interest in April. As of April 15th, there was short interest totaling 27,969 shares, a decline of 69.3% from the March 31st total of 91,217 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 64,190 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent quarter. Hedge funds and other institutional investors own 8.23% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

VivoSim Labs Stock Performance

Shares of NASDAQ VIVS opened at $1.46 on Monday. The firm’s 50-day moving average price is $1.74 and its 200-day moving average price is $2.04. The stock has a market capitalization of $3.81 million, a price-to-earnings ratio of -0.46 and a beta of 1.43. VivoSim Labs has a 12-month low of $1.25 and a 12-month high of $5.30.

VivoSim Labs (NASDAQ:VIVS) last announced its earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. The business had revenue of $0.03 million for the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.